High-dose busulfan, melphalan, and thiotepa followed by autologous peripheral blood stem cell transplantation in patients with aggressive lymphoma or relapsed Hodgkin's disease

Biology of Blood and Marrow Transplantation

Volumn 3, Issue 5, 1997, Pages 261-266

  Schiffman, Kathy ^a   Buckner, C Dean ^a   Maziarz, Richard ^b   Maloney, David G ^a   Appelbaum, Frederick R ^a   Press, Oliver ^c   Gooley, Ted ^a   Holmberg, Leona ^a   Lilleby, Kathy ^a   Clift, Reginald ^a   Zuckerman, Norman ^a   Klarnet, Jay ^a   Weaver, Charles ^a   Chauncey, Thomas ^d   Bensinger, William I ^a  

^a Fred Hutchinson Cancer Research Center   (United States)

^b OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

^c UNIVERSITY OF WASHINGTON   (United States)

^d VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

Autologous stem cell transplant; Hodgkin's Disease; Non Hodgkin's lymphoma

Indexed keywords

ANTINEOPLASTIC AGENT; BUSULFAN; MELPHALAN; THIOTEPA;

ADOLESCENT; ADULT; AGED; ARTICLE; DISEASE FREE SURVIVAL; FEMALE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HODGKIN DISEASE; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; MALE; MIDDLE AGED; MORTALITY; MULTIMODALITY CANCER THERAPY; NONHODGKIN LYMPHOMA; REMISSION; SALVAGE THERAPY; SURVIVAL; TREATMENT OUTCOME; WHOLE BODY RADIATION;

ADOLESCENT; ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BUSULFAN; COMBINED MODALITY THERAPY; DISEASE-FREE SURVIVAL; FEMALE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HODGKIN DISEASE; HUMANS; LYMPHOMA, NON-HODGKIN; MALE; MELPHALAN; MIDDLE AGED; REMISSION INDUCTION; SALVAGE THERAPY; SURVIVAL ANALYSIS; THIOTEPA; TRANSPLANTATION CONDITIONING; TREATMENT OUTCOME; WHOLE-BODY IRRADIATION;

EID: 0031263736     PISSN: 10838791     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (27)

1. Petersen FB, Appelbaum FR, Hill R, Fisher LD, Bigelow CL, Sanders JE, Sullivan KM, Bensinger WI, Witherspoon RP, Storb R, Clift RA, Fefer A, Press OW, Weiden PL, Singer J, Thomas ED, Buckner CD: Autologous marrow transplantation for malignant lymphoma: a report of 101 cases from Seattle. J Clin Oncol 8:638, 1990.
2. Horning SJ, Negrin RS, Chao NJ, Long GD, Hoppe RT, Blume KG: Fractionated total-body irradiation, etoposide, and cyclophosphamide plus autografong in Hodgkin's disease and non-Hodgkin's lymphoma. J Clin Oncol 12:2552, 1994.
3. Philip T, Guglielmi C, Hagenbeek A, Somers R, Van der Lelie H, Bron D, Sonneveld P, Gisselbrecht, Cahn J, Harousseau J, Coiffier B, Biron P, Mandell F, Chauvin F: Autologous bone marrow transplantation as compared with salvage chemotherapy in relapses of chemotherapy-sensitive non-Hodgkin's lymphoma. N Engl J Med 333:1540, 1995.
4. Appelbaum FR, Sullivan KM, Buckner CD, Clift RA, Deeg HJ, Fefer A, Hill R, Mortimer J, Neiman PE, Sanders JE, Singer J, Stewart P, Storb R, Thomas ED: Treatment of malignant lymphoma in 100 patients with chemotherapy, total body irradiation, and marrow transplantation. J Clin Oncol 5:1340, 1987.
5. Horning SJ, Negrin RS, Chao NJ, Long GD, Tiemey K, Hoppe RT, Blume KG: High dose etoposide regimens and autologous bone marrow transplantation (ABMT) for malignant lymphoma: results in 202 consecutive patients (pts). Proc ASCO 12:382, 1993. [abstract]
6. Weaver CH, Petersen FB, Appelbaum FR, Bensinger WI, Press O, Martin P, Sandmaier B, Deeg HJ, Hansen JA, Brunvand M, Rowley S, Benyunes K, Chauncey T, Fefer A, Hackman R, Gooley T, Schiffman K, Storb R, Sullivan KM, Weiden P, Witherspoon R, Buckner CD: High-dose fractionated total-body irradiation, etoposide, and cyclophosphamide followed by autologous stem cell support in patients with malignant lymphoma. J Clin Oncol 12:2559, 1994.
7. Weaver CH, Appelbaum FR, Petersen FB, Clift R, Singer J, Press O, Bensinger W, Bianco J, Martin P, Anasetti C, Badger C, Deeg J, Doney K, Hansen JA, Petersdorf E, Rowley S, Storb R, Sullivan K, Witherspoon R, Weiden P, Buckner CD: High-dose cyclophosphamide, carmustine and etoposide followed by autologous bone marrow transplantation in patients with lymphoid malignancies who have received dose-limiting radiation therapy. J Clin Oncol 11:1329, 1993.
8. Martelli M, Vignetti M, Zinzani PL, Gherlinzoni F, Meloni G, Fiacchini M, De Sanctis V, Papa G, Martelli MF, Calabresi F, Tura S, Mandelli F: High-dose chemotherapy followed by autologous bone marrow transplantation versus dexamethasone, cisplatin, and cytarabine in aggressive non-Hodgkin's lymphoma with partial response to front-line chemotherapy: a prospective randomized Italian multicenter study. J Clin Oncol 14:534, 1996.
9. Schiffman KS, Bensinger WI, Appelbaum FR, Rowley S, Lilleby K, Clift RA, Weaver CH, Demirer T, Sanders JE, Petersdorf S, Gooley T, Weiden P, Zuckerman N, Montgomery P, Maziarz R, Klarnet JP, Rivkin S, Trueblood K, Storb R, Holmberg L, Buckner CD: Phase II study of high-dose busulfan, melphalan and thiotepa with autologous peripheral blood stem cell support in patients with malignant disease. Bone Marrow Transplant 17:943, 1996.
10. Weaver CH, Bensinger WI, Appelbaum FR, Lilleby K, Sandmaier B, Brunvand M, Rowley S, Petersdorf S, Rivkin S, Gooley T, Weiden P, Zuckerman N, Montgomery P, Trueblood K, Klarnet J, Buckner CD: Phase I study of high-dose busulfan, melphalan and thiotepa with autologous stem cell support in patients with refractory malignancies. Bone Marrow Transplant 14:813, 1994.
11. van der Jagt RHC, Appelbaum FR, Petersen FB, Bigelow CL, Fisher LD, Schoch GH, Buckner CD, Sanders J, Storb R, Sullivan KM, Thomas ED: Busulfan and cyclophosphamide as a preparative regimen for bone marrow transplantation in patients with prior chest radiotherapy. Bone Marrow Transplant 8:211, 1991.
12. Lazarus HM, Reed MD, Spitzer TR, Rabaa MS, Blumer JL: High-dose II thiotepa and cryopreserved autologous bone marrow transplantation for therapy of refractory cancer. Cancer Treat Rep 71:689, 1987.
13. Lazarus HM, Herzig RH, Graham-Pole J, Wolff SN, Phillips GL, Strandjord S, Hurd D, Forman W, Gordon EM, Coccia P, Gross S, Herzig GP: Intensive melphalan chemotherapy and cryopreserved autologous bone marrow transplantation for the treatment of refractory cancer. J Clin Oncol 1:359, 1983.
14. Hill R: The Non-Hodgkin's Lymphoma Pathologic Classification Project: National Cancer Institute sponsored study of classifications of non-Hodgkin's lymphomas: summary and description of a working formulation for clinical usage. Cancer 49: 2112, 1982.
15. Lukes RJ, Butler JJ: The pathology and nomenclature of Hodgkin's disease. Cancer Res 26:1063, 1966.
16. Bearman SI, Appelbaum FR, Buckner CD, Petersen FB, Fisher LD, Clift RA, Thomas ED: Regimen-related toxicity in patients undergoing bone marrow transplantation. J Clin Oncol 6:1562, 1988.
17. Shubart MC, McDonald GB: Gastrointestinal and hepatic complications. In: Forman SJ, Blume KG, Thomas ED (eds) Bone Marrow Transplantation. Boston, MA: Blackwell Scientific Publications, 454, 1994.
18. Crawford SW: Critical care and respiratory failure. In: Forman SJ, Blume KG, Thomas ED (eds) Bone Marrow Transplantation. Boston, MA: Blackwell Scientific Publications, 513, 1994.
19. Bensinger W, Singer J, Appelbaum F, Lilleby K, Longin K, Rowley S, Clarke E, Clift R, Hansen J, Shields T, Storb R, Weaver C, Weiden P, Buckner CD: Autologous transplantation with peripheral blood mononuclear cells collected after administration of recombinant granulocyte stimulating factor. Blood 81:3158, 1993.
20. Press OW, Livingston R, Mortimer J, Collitis C, Appelbaum F: Treatment of relapsed non-Hodgkin's lymphomas with dexamethasone, high-dose cytarabine, and cisplatin before marrow transplantation. J Clin Oncol 9:423, 1991.
21. Kaplan EL, Meier P: Nonparametric estimation from incomplete observations. J Am Stat Assoc 53:457, 1958.
22. Pepe MS, Longton G, Pettinger M, Mori M, Fisher LD, Storb R: Summarizing data on survival, relapse, and chronic graft-versus-host disease after bone marrow transplantation: motivation for and description of new methods. Br J Haematol 83:602, 1993.
23. Pecego R, Hill R, Appelbaum FR, Amos D, Buckner CD, Fefer A, Thomas ED: Interstitial pneumonitis following autologous bone marrow transplantation. Transplantation 42:515, 1986.
24. Clark JG, Hansen JA, Hertz MI, Parkman R, Jensen L, Peavy HH: Idiopathic pneumonia syndrome following bone marrow transplantation. Am Rev Respir Dis 147:1601, 1993.
25. Wheeler C, Antin JH, Churchill WH, Come SE, Smith BR, Bubley GJ, Rosenthal DS, Rappaport JM, Ault KA, Schnipper LE, Eder JP: Cyclophosphamide, carmustine, and etoposide with autologous bone marrow transplantation in refractory Hodgkin's disease and non-Hodgkin's lymphoma: a dose-finding study. J Clin Oncol 8:648, 1990.
26. Brunvand MW, Bensinger WI, Soll E, Weaver CH, Rowley SD, Appelbaum FR, Lilleby K, Clift RA, Gooley TA, Press OW, Fefer A, Storb R, Sanders JE, Martin PL, Chauncey T, Maziarz RT, Zuckerman N, Montgomery P, Dorn R, Weiden PL, Demirer T, Holmberg LA, Schiffman K, McSweeney PA, Maloney DG, Buckner CD: High-dose fractionated totalbody irradiation, etoposide and Cyclophosphamide for treatment of malignant lymphoma: comparison of autologous bone marrow and peripheral blood stem cells. Bone Marrow Transplant 18:131, 1996.
27. Stockerl-Goldstein KE, Horning SF, Negrin RS, Chao NF, Hu WW, Long GD, Hoppe RT, Amylon MD, Brown BW, Wong RM, Blume KG: Influence of preparatory regimen and source of hematopoietic cells on outcome of autotransplantation for non-Hodgkin's lymphoma. Biol Blood and Marrow Transplant 2:76, 1996.